March 23 (Reuters) - Nuvo Pharmaceuticals Inc NRI.TO :
* NUVO PHARMACEUTICALS™ ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END RESULTS
* Q4 REVENUE C$4.5 MILLION VERSUS C$5.6 MILLION
* QTRLY TOTAL REVENUE WAS $4.5 MILLION COMPARED TO $5.6 MILLION
* QTRLY NET LOSS FROM CONTINUING OPERATIONS WAS $0.2 MILLION VERSUS NET INCOME FROM CONTINUING OPERATIONS OF $1.7 MILLION
* CASH AND SHORT-TERM INVESTMENTS WERE $10.4 MILLION AS AT DECEMBER 31, 2017 COMPARED TO $17.7 MILLION AS AT SEPTEMBER 30, 2017
* NUVO PHARMACEUTICALS - NOT YET SEEN SIGNIFICANT NEGATIVE EFFECT FROM HORIZON'S SALES FORCE REDUCTION THAT MIGHT IMPACT BOTTLE ORDERING PATTERNS
* REDUCTION IN SAMPLE PRODUCT ORDERS FROM HORIZON HAD A NEGATIVE IMPACT ON COMPANY'S 2017 FINANCIAL RESULTS